RIVAROXABAN (Xarelto®)
Clinical Indication
Preventing atherothrombotic events in people with coronary or peripheral artery disease
Comments
In line with NICE TA607
Date of classification
January 2020
Yellow
Specialist recommendation: Medicines initiated (and stabilised where appropriate) or recommended by a specialist service for prescribing in primary care. Requests should be clearly communicated either through written communication including using approved paperwork if available or verbal means as appropriate .